Forodesine

DB06185InvestigationalSmall molecule

Forodesine is a highly potent, orally active, rationally designed PNP inhibitor that has shown activity in preclinical studies with malignant cells and clinical utility against T-cell acute lymphoblastic leukemia and... Additional preliminary findings support its use for the management of some B-cell malignancies.

Mechanism: Pharmacologically active on Purine nucleoside phosphorylase
Curator reviewed
Primary indication: Investigated for use/treatment in lymphoma (non-hodgkin's) and leukemia (lymphoid).Curator reviewed
Formula / weight: C₁₁H₁₄N₄O₄ · 266.2533 g/mol (avg)
Also known as: Immucillin H · Immucillin-H
Code names: BCX-1777

Resolves to

Compound

UNII426X066ELKCAS209799-67-7ChEMBLCHEMBL218291ChEBI43362PubChem444499KEGGD06596

Structure

InChIKeyIWKXDMQDITUYRK-KUBHLMPHSA-NSMILESOC[C@H]1N[C@H]([C@H](O)[C@@H]1O)C1=CNC2=C1N=CNC2=O

Targets

P00491PNP

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Forodesine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account